logo
Why vaccine makers aren't worried about Trump administration cuts

Why vaccine makers aren't worried about Trump administration cuts

Yahoo23-04-2025

Large and mid-cap vaccine makers are, as of now, unworried about their 2025 pipelines in the face of research funding declines by the Trump administration and a drop in biotech funding.
That's what some of the top vaccine-maker executives told Yahoo Finance this week at the World Vaccine Congress in Washington, D.C.
These executives believe there will be no impact from the funding cuts and policies coming down from the Trump administration, while others view it as a four-year storm they will just have to weather before being able to carry on as usual afterward.
"We're in this for the long game. We believe in vaccines, in the value of vaccines, and what they bring to public health. Infectious diseases aren't going to go away, so the need for vaccines is going to remain long-term," said Sally Mossman, head of research portfolio strategy at Sanofi (SNY).
While large-cap pharma companies can fund most of their research and development internally, they have been known to rely on federal funding for the earliest stages of research via partnerships with research agencies like the National Institutes of Health (NIH). They also partner with smaller biotech companies and academic research centers.
But that dynamic is drastically changing under the Trump administration.
The NIH has already slashed billions in research funding for top universities and cut funding for one mRNA vaccine study and other studies related to vaccine access and hesitancy. (The trickle-up effect on large caps is yet to be determined.) At the same time, funding for biotech — potential partners or acquisition targets for the big players — is also on the decline as investors continue to lose interest in the post-pandemic world.
The view from executives at Pfizer (PFE), Moderna (MRNA), GSK (GSK), Sanofi, and Merck (MRK)? They'll be fine in the long run.
Each company has between a dozen and two dozen vaccine candidates actively being developed and tested in its pipeline. Despite recent announcements of cuts and key leadership departures at the FDA, the companies have not experienced any disruptions in communicating with the FDA about the progress of these vaccines.
GSK global medical lead for vaccines Rafik Bekkat-Berkani said that paying attention to the (short-term) noise was important, but "whether we need to let this noise dictate what we do, the answer is no."
Sanofi's Mossman noted that as the company focuses on the US versus global markets, one goal is always to ensure a return on investment for whatever vaccine is being developed.
It's no wonder since vaccines make up a good chunk of revenue, even for large-cap pharmaceuticals with diversified portfolios. Among the companies present, UK-based GSK and France-based Sanofi saw vaccines sales account for about 25% of total revenues in 2024. Pfizer counted its top-selling vaccines as 20% of its $64 billion in revenues last year. Merck saw top-selling vaccine sales contribute less than 20% to its $64 billion in revenues.
Moderna is the most heavily reliant on federal funding for some of its pipeline candidates and has only two vaccines on the market: its COVID-19 vaccine and a respiratory syncytial virus (RSV) vaccine for older adults. The two contributed 100% to the company's $3.2 billion in sales last year.
Meanwhile, Health and Human Services Secretary Robert F. Kennedy Jr. has expressed an interest in eliminating some childhood vaccines due to concerns about their potential impacts on children. That doesn't worry the companies as much, because adult vaccines are a newer and profitable market to target, the executives said.
"I think we have to recognize ... the low-hanging fruit's already (done) to a large degree," Merck associate vice president of vaccines Jeffrey Roberts said.
It's why more novel viruses and diseases are being targeted — and those that have been targeted globally for some time, like Lyme disease. Other areas are in early stages, like a vaccine for acne at Sanofi.
Mossman explained that while some might consider acne an unimportant target, she sees it as a solution to an inflammatory skin problem for about 22 million patients.
Merck's Roberts said the remaining vaccines to target are "tough nuts to crack."
Which is why the group collectively waved off any threats from the Trump administration's moves.
"It comes down to 'Don't worry about the money. If you make something that has value, people are going to value it,'" Roberts said.
Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee on social media platforms X, LinkedIn, and Bluesky @AnjKhem.
Click here for in-depth analysis of the latest health industry news and events impacting stock prices

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pentagon Is Reviewing Deal to Equip Australia With Nuclear Submarines
Pentagon Is Reviewing Deal to Equip Australia With Nuclear Submarines

New York Times

time10 minutes ago

  • New York Times

Pentagon Is Reviewing Deal to Equip Australia With Nuclear Submarines

The Trump administration is reviewing whether a security pact between the United States, Britain and Australia meant to equip Australia with nuclear submarines is 'aligned with the president's America First agenda,' a U.S. defense official said on Wednesday. When the deal was reached under President Joseph R. Biden Jr.'s administration in 2021, it was billed as crucial for countering China's growing military influence in the Asia Pacific. Now, its review appears to reinforce President Trump's skeptical and transactional approach to longstanding alliances, including demands that allies spend more on their own defense. The Pentagon official said the review would ensure that the pact, known as Aukus, met 'common-sense, America First criteria,' including ensuring that U.S. forces are at 'the highest readiness,' that allies are doing their part, and that 'the defense industrial base is meeting our needs.' The review was first reported by The Financial Times. Australia's defense minister, Richard Marles, said both Australia and Britain had been notified about the review and that all three nations were still committed to the deal. 'We've been aware of this for some time. We welcome it,' Mr. Marles said in a radio interview with ABC Melbourne on Thursday, Australia time. 'It's something which is perfectly natural for an incoming administration to do.' Australia sees the Aukus agreement as central to its defense strategy in the coming decades in a region increasingly shaped by China's assertive military posturing. Nuclear submarines can travel much farther without detection than conventional ones can and would enable the Australian Navy to greatly extend its reach. Under the pact, Australia is scheduled to receive secondhand Virginia-class nuclear submarines from the United States in the 2030s while scaling up the capacity to build its own, using a British design. But there has been concern in both Washington and Canberra about whether the United States can build new submarines to replenish its fleet quickly enough for the older ones to be transferred to Australia. Elbridge Colby, the U.S. under secretary of defense for policy, said during his Senate confirmation hearing in March that he was skeptical about the pragmatic feasibility of the deal. The Financial Times reported that Mr. Colby was heading up the Pentagon review. 'So if we can produce the attack submarines in sufficient number and sufficient speed, then great,' Mr. Colby said at the hearing. 'But if we can't, that becomes a very difficult problem.' Even before the review was announced, concern and anxiety had been building in Australia over whether it could continue to depend on its longstanding relationship with the United States, given the Trump administration's treatment of allies. Mr. Marles, the Australian defense minister, said in the radio interview that he was confident the Aukus deal would proceed because 'it's in the interests of the United States to continue to work with Australia.' Michael D. Shear contributed reporting from Washington.

Bloomberg Daybreak Asia: Trump Says He'll Set Unilateral Tariffs; China's Biotech Boom
Bloomberg Daybreak Asia: Trump Says He'll Set Unilateral Tariffs; China's Biotech Boom

Bloomberg

time15 minutes ago

  • Bloomberg

Bloomberg Daybreak Asia: Trump Says He'll Set Unilateral Tariffs; China's Biotech Boom

US equity-index futures dipped along with the dollar after President Donald Trump said he will set unilateral tariff rates within two weeks, dialing up trade tensions once again. The comments come a day after Chinese and US officials struck a positive tone following their talks to dial down trade tensions. Amid US talking with countries including India and Japan to lower the levies, some investors see Trump's comments as an effort to ramp up urgency in talks. We talk markets with Zachary Hill, Head of Portfolio Management at Horizon Investments. Plus - China's biotech industry is gaining momentum, with Pfizer and Bristol-Myers Squibb making billion-dollar deals with Chinese companies to license experimental cancer drugs. The industry is expected to continue growing, driven by factors such as US President Donald Trump's economic policies, cheaper and easier human testing in China, and an abundance of young and affordable engineering talent. We check in with Shuli Ren, Bloomberg Opinion Columnist, for a closer look at the sector.

Elon Musk's favorability among Republicans dropped 16 points since March, Quinnipiac says
Elon Musk's favorability among Republicans dropped 16 points since March, Quinnipiac says

CNBC

time31 minutes ago

  • CNBC

Elon Musk's favorability among Republicans dropped 16 points since March, Quinnipiac says

Elon Musk's official role in the Trump administration recently came to an end. Many Republicans won't be sad to see less of him, according to the results of Quinnipiac University's latest public opinion survey. While a majority of Republicans still hold a favorable view of Musk, the number fell to 62% in the poll out Wednesday, down from 78% in March, Quinnipiac said. Overall, the Quinnipiac poll found that 30% of self-identified voters surveyed in the U.S. hold a favorable opinion of Musk, according to polling from June 5 to June 9. Republican and Democratic voters remain deeply divided in their views of the world's richest man, who contributed nearly $300 million to propel President Donald Trump back to the White House. Only 3% of Democrats surveyed said they held a favorable of view of the Tesla CEO, who was once seen as an environmental leader appealing to liberal values. Musk didn't respond to a request for comment. Musk and Trump had a very public falling out last week that started with Musk's disapproval of the president's spending bill and escalated into an all-out war of words that played out on social media. Musk said on Wednesday that he regretted some of the posts he made about Trump last week, adding that "they went too far." Even with a slide in his favorability, Musk is still popular among Republicans after his time running the Department of Government Efficiency (DOGE), an effort to dramatically slash the size of the federal government. Among the Republican respondents to the early June poll, 80% rated Musk and DOGE's work as either excellent or good, while 13% said it was either not so good or poor. In the March poll, 82% of Republicans surveyed said they thought Musk and DOGE were helping the country. Read the full survey results here.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store